Skip to main content
Clinical Trials/NCT00125086
NCT00125086
Completed
Not Applicable

Platelets in Acute Wounds: A Punch Biopsy Study (PAWS II)

Medtronic1 site in 1 country4 target enrollmentJuly 2005
ConditionsWounds

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Wounds
Sponsor
Medtronic
Enrollment
4
Locations
1
Primary Endpoint
Time to 100% wound closure, measured at Days 7, 14, 21, 28, 35
Status
Completed
Last Updated
20 years ago

Overview

Brief Summary

This study will examine whether platelet gel positively affects wound healing. Platelet gel will be used to treat punch biopsy wounds and the results will be compared to results from wounds treated with a control treatment.

Detailed Description

Platelets contribute to the healing process in soft tissue by providing the initial hemostasis that occurs following injury, a framework for fibrin matrix formation and contribution of growth factors. According to the US National Institutes of Health, surgical procedures are considered a form of controlled injury, so many of the complications faced by surgery patients are very similar to those faced by trauma patients. Scientists are currently investigating ways to treat wounds caused by trauma, burns or surgical inventions with biological agents (i.e. growth factors) or new drugs. Growth factor priming of acute wound sites pre-activates the cellular and molecular components of tissue repair, prior to tissue injury. Objectives are aimed at gathering information to establish evidence that autologous platelet gel positively effects the healing of acute wounds.

Registry
clinicaltrials.gov
Start Date
July 2005
End Date
February 2006
Last Updated
20 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medtronic

Eligibility Criteria

Inclusion Criteria

  • Normal volunteers
  • 18 years old or older

Exclusion Criteria

  • Pregnant or lactating
  • Diabetic, keloid former, collagen vascular disease
  • Body mass index \>30kg/m2
  • Known history of HIV/AIDS; Hepatitis A, B, or C
  • Bleeding disorder
  • Aspirin, non-steroidal anti-inflammatory drug (NSAID) or anticoagulant user
  • Cancer, or treatment for cancer, in past 5 years

Outcomes

Primary Outcomes

Time to 100% wound closure, measured at Days 7, 14, 21, 28, 35

Secondary Outcomes

  • Measurements of wound depth at each visit
  • Measurement of residual scarring at 6 months post wounding

Study Sites (1)

Loading locations...

Similar Trials